Plain-English translation of NCT06821100 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called thymalfasin (also known as thymosin alpha 1 or Ta1) to see if it can help your immune system respond better to a COVID-19 booster vaccine. The medication has previously been shown to stimulate your immune system to fight infections. Researchers want to find out if giving this treatment before vaccination can increase how well your body protects itself against COVID-19.
As we age, our immune system becomes less responsive to vaccines, which means older adults may not build as strong a protection from COVID-19 booster shots. This study is exploring whether this medication can enhance your immune response and help make the vaccine more effective for people 65 and older.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either no pre-treatment, one injection of the medication before vaccination, or two injections of the medication (given a few days apart) before your COVID-19 booster. Researchers will monitor your safety and measure how well your immune system responds to the vaccine through blood tests and follow-up visits over several weeks.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States